JPWO2019195813A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019195813A5 JPWO2019195813A5 JP2020554433A JP2020554433A JPWO2019195813A5 JP WO2019195813 A5 JPWO2019195813 A5 JP WO2019195813A5 JP 2020554433 A JP2020554433 A JP 2020554433A JP 2020554433 A JP2020554433 A JP 2020554433A JP WO2019195813 A5 JPWO2019195813 A5 JP WO2019195813A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- pharmaceutically acceptable
- acceptable salt
- item
- gaboxadol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000003839 salts Chemical class 0.000 claims description 40
- 239000008194 pharmaceutical composition Substances 0.000 claims description 34
- ZXRVKCBLGJOCEE-UHFFFAOYSA-N Gaboxadol Chemical compound C1NCCC2=C1ONC2=O ZXRVKCBLGJOCEE-UHFFFAOYSA-N 0.000 claims description 29
- 229950004346 gaboxadol Drugs 0.000 claims description 29
- 208000011117 substance-related disease Diseases 0.000 claims description 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 12
- 235000019788 craving Nutrition 0.000 claims description 11
- 239000003814 drug Substances 0.000 claims description 11
- 229940124597 therapeutic agent Drugs 0.000 claims description 11
- 208000025569 Tobacco Use disease Diseases 0.000 claims description 10
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 claims description 8
- 241000208125 Nicotiana Species 0.000 claims description 7
- 235000002637 Nicotiana tabacum Nutrition 0.000 claims description 7
- 206010057852 Nicotine dependence Diseases 0.000 claims description 7
- 241000218236 Cannabis Species 0.000 claims description 6
- 239000000380 hallucinogen Substances 0.000 claims description 6
- 239000000932 sedative agent Substances 0.000 claims description 5
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 claims description 4
- 229960001948 caffeine Drugs 0.000 claims description 4
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 claims description 4
- 208000035475 disorder Diseases 0.000 claims description 4
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 claims description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 3
- 208000026251 Opioid-Related disease Diseases 0.000 claims description 3
- 206010043903 Tobacco abuse Diseases 0.000 claims description 3
- 229960002715 nicotine Drugs 0.000 claims description 3
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 claims description 3
- 229940005483 opioid analgesics Drugs 0.000 claims description 3
- 229940125723 sedative agent Drugs 0.000 claims description 3
- 239000000021 stimulant Substances 0.000 claims description 3
- 239000000126 substance Substances 0.000 claims description 3
- 208000007848 Alcoholism Diseases 0.000 claims description 2
- 230000001624 sedative effect Effects 0.000 claims description 2
- 208000025746 alcohol use disease Diseases 0.000 claims 1
- 208000024891 symptom Diseases 0.000 description 3
- 230000002265 prevention Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 1
- 230000005586 smoking cessation Effects 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862653641P | 2018-04-06 | 2018-04-06 | |
| US62/653,641 | 2018-04-06 | ||
| US201862654786P | 2018-04-09 | 2018-04-09 | |
| US62/654,786 | 2018-04-09 | ||
| PCT/US2019/026218 WO2019195813A1 (en) | 2018-04-06 | 2019-04-06 | Use of gaboxadol in the treatment of substance use disorders |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021521103A JP2021521103A (ja) | 2021-08-26 |
| JP2021521103A5 JP2021521103A5 (https=) | 2022-04-11 |
| JPWO2019195813A5 true JPWO2019195813A5 (https=) | 2022-04-11 |
Family
ID=68101544
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020554433A Pending JP2021521103A (ja) | 2018-04-06 | 2019-04-06 | 物質使用障害の処置におけるガボキサドールの使用 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20190321341A1 (https=) |
| EP (1) | EP3761979A4 (https=) |
| JP (1) | JP2021521103A (https=) |
| KR (1) | KR20210039324A (https=) |
| CN (1) | CN112601524A (https=) |
| AU (1) | AU2019249277A1 (https=) |
| CA (1) | CA3095682A1 (https=) |
| IL (1) | IL277805A (https=) |
| MX (1) | MX2020010545A (https=) |
| WO (1) | WO2019195813A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11123332B2 (en) | 2018-11-21 | 2021-09-21 | Certego Therapeutics Inc. | Gaboxadol for reducing risk of suicide and rapid relief of depression |
| MX2022014599A (es) | 2020-05-20 | 2022-12-16 | Certego Therapeutics Inc | Gaboxadol deuterado en anillo y su uso para el tratamiento de trastornos psiquiatricos. |
| WO2023168023A1 (en) | 2022-03-04 | 2023-09-07 | Reset Pharmaceuticals, Inc. | Co-crystals or salts comprising psilocin |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6890951B2 (en) * | 1998-08-05 | 2005-05-10 | Brookhaven Science Associates Llc | Treatment of addiction and addiction-related behavior |
| IT1313585B1 (it) * | 1999-07-30 | 2002-09-09 | Neuroscienze S C A R L | Uso di agonisti dei recettori gabab per la terapia di mantenimentodell'astinenza da nicotina in soggetti nicotino-dipendenti. |
| US20050192271A1 (en) * | 2003-07-15 | 2005-09-01 | Hythiam, Inc. | Use of selective chloride channel modulators to treat alcohol and/or stimulant substance abuse |
| US20020165217A1 (en) * | 2001-05-01 | 2002-11-07 | Pfizer Inc. | Combination treatment for anxiety and depression |
| US20050234093A1 (en) * | 2003-06-25 | 2005-10-20 | H. Lundbeck A/S | Treatment of depression and other affective disorders |
| CL2004001603A1 (es) * | 2003-06-25 | 2005-05-27 | Lundbeck & Co As H | Uso de gabaxadol para preparar un medicamento util para el tratamiento del dolor neuropatico. |
| DK1641456T3 (da) * | 2003-06-25 | 2010-06-21 | Lundbeck & Co As H | Gaboxadol til behandling af depression og andre affektive lidelser |
| EP1868593A2 (en) * | 2005-04-07 | 2007-12-26 | Hythiam, Inc. | Improved methods of and compositions for the prevention of anxiety, substance abuse, and dependence |
| CN101168056A (zh) * | 2006-10-26 | 2008-04-30 | 昆明艾迪康生物科技有限公司 | 混合物制剂 |
| CN101168058A (zh) * | 2006-10-26 | 2008-04-30 | 昆明艾迪康生物科技有限公司 | 一种混合物制剂 |
| CN101168057A (zh) * | 2006-10-26 | 2008-04-30 | 昆明艾迪康生物科技有限公司 | 多巴胺激动剂制剂 |
| GB0810063D0 (en) * | 2008-06-03 | 2008-07-09 | Renovo Ltd | Medicaments and methods for inhibition of scarring |
| WO2011069860A1 (en) * | 2009-12-08 | 2011-06-16 | Chr. Hansen A/S | Novel use for the treatment of metabolic endotoxemia |
| MX2013002162A (es) * | 2010-08-24 | 2013-04-05 | Univ California | Metodos para tratar la intoxicacion con alcohol, transtornos debido al consumo de alcohol y alcolismo que comprenden la administracion de dihidromiricetina. |
-
2019
- 2019-04-06 MX MX2020010545A patent/MX2020010545A/es unknown
- 2019-04-06 JP JP2020554433A patent/JP2021521103A/ja active Pending
- 2019-04-06 KR KR1020207032162A patent/KR20210039324A/ko not_active Withdrawn
- 2019-04-06 US US16/377,172 patent/US20190321341A1/en not_active Abandoned
- 2019-04-06 AU AU2019249277A patent/AU2019249277A1/en not_active Abandoned
- 2019-04-06 CN CN201980037011.8A patent/CN112601524A/zh active Pending
- 2019-04-06 EP EP19781960.0A patent/EP3761979A4/en not_active Withdrawn
- 2019-04-06 WO PCT/US2019/026218 patent/WO2019195813A1/en not_active Ceased
- 2019-04-06 CA CA3095682A patent/CA3095682A1/en active Pending
-
2020
- 2020-10-05 IL IL277805A patent/IL277805A/en unknown
-
2022
- 2022-04-19 US US17/723,979 patent/US20220241253A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Freedman | Exacerbation of schizophrenia by varenicline | |
| US10376657B2 (en) | Medicinal vapor filtration system | |
| JP4377586B2 (ja) | 炎症性疾患治療用のニコチン性受容体アゴニスト | |
| Frishman et al. | Nicotine and non-nicotine smoking cessation pharmacotherapies | |
| WO2015191841A1 (en) | Novel methods of treating or preventing fibrotic lung diseases | |
| JP2021521103A5 (https=) | ||
| JP2025081331A5 (https=) | ||
| Frishman | Smoking cessation pharmacotherapy | |
| Tzankova et al. | Cytisine—from ethomedical use to the development as a natural alternative for smoking cessation | |
| JPWO2019195813A5 (https=) | ||
| US9724340B2 (en) | Antitussive compositions and methods | |
| Compton | The need to incorporate smoking cessation into behavioral health treatment | |
| Uzbay | Hypericum perforatum and substance dependence: a review | |
| US20100143270A1 (en) | Therapeutic cotinine compositions | |
| MX2020010545A (es) | Uso de gaboxadol en el tratamiento de trastornos por consumo de sustancias. | |
| JP7588773B2 (ja) | グルタミン酸２ｂ受容体拮抗薬及びシグマ受容体作動薬の鎮咳薬としての使用 | |
| US20060142180A1 (en) | Cholinergic modulation of microglial activation via alpha-7 nicotinic receptors | |
| US20150258109A1 (en) | Low dose administration of ibogaine for treating nicotine addiction and preventing relapse of nicotine use | |
| Chirila et al. | Current knowledge on bupropion and varenicline clinical efficacy in nicotine dependence | |
| Faulkner et al. | Pharmacologic treatment of chronic obstructive pulmonary disease: past, present, and future | |
| Nia | Opioid addiction and borderline personality disorder | |
| Arosio et al. | Comparative efficacy of ketanserin and pentoxiphylline in treatment of Raynaud's phenomenon | |
| US20020168403A1 (en) | Compositions and therapy for substance addiction | |
| Bussone et al. | Efficacy and tolerability of sumatriptan in the treatment of multiple migraine attacks | |
| WO2020229388A1 (en) | Mirtazapine for use in medication overuse headache based on tension-type headache |